DSIP + Selank: Sleep & Anxiety Relief
A sleep and stress-reduction stack combining DSIP's direct sleep-promoting and sleep architecture-improving properties with Selank's daytime anxiolytic and mood-stabilising effects. DSIP is proposed to increase slow-wave delta sleep and normalise circadian sleep patterns by modulating hypothalamic sleep-wake centres, while Selank reduces anxiety, cortisol reactivity, and cognitive stress load that often prevents sleep onset. The combination targets both the quality of sleep and the psychological barriers to achieving it.
Safety Notes
DSIP (delta sleep-inducing peptide) is a research compound; the majority of human data originates from 1970s–1980s studies with limited modern independent replication. Selank is a Russian-developed synthetic peptide not FDA-approved in the United States. Potential interactions with existing sleep medications, benzodiazepines, or anxiolytics are not characterised and warrant caution when combining. No formal safety data exists for this combination.
Peptides in This Stack
- 1DSIPRecovery
Proposed to increase slow-wave delta sleep duration and normalise disrupted sleep architecture by modulating hypothalamic sleep-wake regulatory centres — the primary sleep-inducing agent of the stack.
- 2SelankCognitive
Reduces pre-sleep anxiety and cortisol reactivity through anxiolytic enkephalin modulation, addressing the psychological barrier to sleep onset that DSIP alone cannot target.
Research References
Preliminary
- Delta-sleep-inducing peptide (DSIP): a reviewNeurosci Biobehav Rev 1984 · PMID 6382008Primary literature is 1980s with limited modern replication
- Effect of Selank on AnxietyEksp Klin Farmakol 2010Russian-language journal, single institute, limited independent Western replication
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.